 |
humanized anti-CD19, Fc engineered, monoclonal antibody with enhanced binding to FcyRIIb |
|---|---|
| Trade Name | Xmab(R)5871 |
| Orphan Indication | Immunoglobulin G4-related disease |
| USA Market Approval | USA |
| USA Designation Date | 2017-05-09 00:00:00 |
| Sponsor | Xencor, Inc.;111 West Lemon Avenue;Monrovia, California, 91016 |
